Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
NCT02860000Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2017
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alisertib in breast cancer, sponsored by Mayo Clinic. Started Jul 2017; status: completed.
02
Drugs
alisertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02860000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02860000.